299 related articles for article (PubMed ID: 34489209)
21. Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study.
Zhang Y; Duncanson L; Brayer J; Reu F; Hansen D; Alsina M; Nishihori T; Ochoa-Bayona J; Liu H; Shain K; Thompson Z; Baz R; Blue B
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e770-e776. PubMed ID: 35504808
[TBL] [Abstract][Full Text] [Related]
22. A nationwide prospective registry of bortezomib-based therapy in light chain (AL) amyloidosis.
Palladini G; Celant S; Milani P; Summa V; Affronti G; Olimpieri PP; Petraglia S; Foli A; Nuvolone M; Merlini G; Russo P;
Leuk Lymphoma; 2022 Jan; 63(1):205-211. PubMed ID: 34448427
[TBL] [Abstract][Full Text] [Related]
23. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival.
Venner CP; Lane T; Foard D; Rannigan L; Gibbs SD; Pinney JH; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD
Blood; 2012 May; 119(19):4387-90. PubMed ID: 22331187
[TBL] [Abstract][Full Text] [Related]
24. Bortezomib-based chemotherapy reduces early mortality and improves outcomes in patients with ultra-high-risk light-chain amyloidosis: a retrospective case control study.
Shen KN; Zhang CL; Tian Z; Feng J; Wang YN; Sun J; Zhang L; Cao XX; Zhou DB; Li J
Amyloid; 2019 Jun; 26(2):66-73. PubMed ID: 31074308
[No Abstract] [Full Text] [Related]
25. Outcome of Cardiac Light-Chain Amyloidosis in the Era of Novel Therapy - A Single-Center Cohort Study of 227 Patients.
Feng J; Zhang C; Shen K; Sun J; Fang Q; Zhang L; Cao X; Zhou D; Li J; Tian Z
Circ J; 2019 Mar; 83(4):775-782. PubMed ID: 30773521
[TBL] [Abstract][Full Text] [Related]
26. [Prognostic value of translocation t(11;14) in primary light-chain amyloidosis treated with bortezomib-based regimen].
Gao YJ; Shen KN; Feng J; Chang L; Li H; Su W; Cao XX; Zhang L; Zhou DB; Li J
Zhonghua Yi Xue Za Zhi; 2022 Sep; 102(36):2854-2860. PubMed ID: 36153870
[No Abstract] [Full Text] [Related]
27. [Treatment of AL-amyloidosis--results from one clinic and review of published experience with new agents (bortezomib, thalidomide and lenalidomide) in AL-amyloidosis].
Adam Z; Pour L; Krejcí M; Zahradová L; Krivanová A; Mardová J; Kovárová L; Stepánková S; Moulis M; Kren L; Veselý K; Svobodová I; Germáková Z; Nedbálková M; Mayer J; Hájek R
Vnitr Lek; 2010 Mar; 56(3):190-209. PubMed ID: 20394205
[TBL] [Abstract][Full Text] [Related]
28. Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies.
Kastritis E; Roussou M; Gavriatopoulou M; Migkou M; Kalapanida D; Pamboucas C; Kaldara E; Ntalianis A; Psimenou E; Toumanidis ST; Tasidou A; Terpos E; Dimopoulos MA
Am J Hematol; 2015 Apr; 90(4):E60-5. PubMed ID: 25580702
[TBL] [Abstract][Full Text] [Related]
29. A comparative study of cyclophosphamide, thalidomide and dexamethasone (CTD) versus bortezomib and dexamethasone (BDex) in light-chain amyloidosis.
Liu B; Wang Y; Ning X; Bai M; Wang D; Zhao J; Zhou M; Sun S
Curr Probl Cancer; 2021 Apr; 45(2):100669. PubMed ID: 33127168
[TBL] [Abstract][Full Text] [Related]
30. Effect of the Presence of t(11;14) for Patients With AL Amyloidosis Treated With Bortezomib-Containing Regimens: Experience From the Amyloidosis Program of Calgary.
Lewis E; McCulloch S; Mahe E; Bahlis N; Neri P; Tay J; Duggan P; Jimenez-Zepeda VH
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):e331-e334. PubMed ID: 37532664
[No Abstract] [Full Text] [Related]
31. [Oral melphalan plus high-dose dexamethasone as first-line therapy for patients with primary light chain amyloidosis].
Zhang CL; Shen KN; Feng J; Cao XX; Mao YY; Zhang L; Su W; Zhou DB; Li J
Zhonghua Xue Ye Xue Za Zhi; 2018 Aug; 39(8):641-644. PubMed ID: 30180464
[No Abstract] [Full Text] [Related]
32. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib.
Manwani R; Cohen O; Sharpley F; Mahmood S; Sachchithanantham S; Foard D; Lachmann HJ; Quarta C; Fontana M; Gillmore JD; Whelan C; Hawkins PN; Wechalekar AD
Blood; 2019 Dec; 134(25):2271-2280. PubMed ID: 31578202
[TBL] [Abstract][Full Text] [Related]
33. Doxycycline Combined With Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Cardiac Light-Chain Amyloidosis: A Multicenter Randomized Controlled Trial.
Shen KN; Fu WJ; Wu Y; Dong YJ; Huang ZX; Wei YQ; Li CR; Sun CY; Chen Y; Miao HL; Zhang YL; Cao XX; Zhou DB; Li J
Circulation; 2022 Jan; 145(1):8-17. PubMed ID: 34503349
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis.
Brennan X; Withers B; Jabbour A; Milliken S; Kotlyar E; Fay K; Ma D; Muthiah K; Hamad N; Dodds A; Bart N; Keogh A; Hayward C; Macdonald P; Moore J
Intern Med J; 2022 Oct; 52(10):1826-1830. PubMed ID: 36266066
[TBL] [Abstract][Full Text] [Related]
35. Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation.
Cornell RF; Zhong X; Arce-Lara C; Atallah E; Blust L; Drobyski WR; Fenske TS; Pasquini MC; Rizzo JD; Saber W; Hari PN
Bone Marrow Transplant; 2015 Jul; 50(7):914-7. PubMed ID: 25915809
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis.
Lamm W; Willenbacher W; Lang A; Zojer N; Müldür E; Ludwig H; Schauer-Stalzer B; Zielinski CC; Drach J
Ann Hematol; 2011 Feb; 90(2):201-6. PubMed ID: 20821326
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).
Jaccard A; Comenzo RL; Hari P; Hawkins PN; Roussel M; Morel P; Macro M; Pellegrin JL; Lazaro E; Mohty D; Mercie P; Decaux O; Gillmore J; Lavergne D; Bridoux F; Wechalekar AD; Venner CP
Haematologica; 2014 Sep; 99(9):1479-85. PubMed ID: 24859879
[TBL] [Abstract][Full Text] [Related]
38. Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study.
Jain T; Kosiorek HE; Kung ST; Shah VS; Dueck AC; Gonzalez-Calle V; Luft S; Reeder CB; Adams R; Noel P; Larsen JT; Mikhael J; Bergsagel L; Stewart AK; Fonseca R
Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):486-492.e1. PubMed ID: 29753692
[TBL] [Abstract][Full Text] [Related]
39. Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen.
Dumas B; Yameen H; Sarosiek S; Sloan JM; Sanchorawala V
Amyloid; 2020 Dec; 27(4):244-249. PubMed ID: 32551974
[TBL] [Abstract][Full Text] [Related]
40. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.
Wechalekar AD; Schonland SO; Kastritis E; Gillmore JD; Dimopoulos MA; Lane T; Foli A; Foard D; Milani P; Rannigan L; Hegenbart U; Hawkins PN; Merlini G; Palladini G
Blood; 2013 Apr; 121(17):3420-7. PubMed ID: 23479568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
